Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 Trial
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
This study evaluated whether depressive symptom severity improved early with extended-release naltrexone and bupropion combination (naltrexone bupropion) compared to a placebo in individuals with moderate/severe methamphetamine use disorder and predicted subsequent use of methamphetamine. This secondary analysis from the Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT-2) trial, which was conducted from May 23, 2017-July 25, 2019, included 326 individuals with a 9-item Patient Health Questionnaire (PHQ-9) score ≥5 at baseline. Repeated-measures mixed model analyses evaluated early (baseline-to-week-4) changes in depressive symptom severity with naltrexone-bupropion versus placebo and provided slope estimates for PHQ-9 change. Additional depression outcomes included response (≥50% reduction in PHQ-9 from baseline) and remission (PHQ-9 ≤4). Methamphetamine treatment response was ascribed if 3 out of 4 urine drug screens were negative during weeks 5 and 6. Logistic regression analyses evaluated whether changes in depression predicted methamphetamine treatment response. Covariates included age, sex, race, ethnicity, and baseline PHQ-9. There was a greater reduction in PHQ-9 scores at week 4 with naltrexone-bupropion versus placebo (estimate = -2.52; standard error = 0.81). At week 4, depression response (odds ratio [OR] = 2.54; 95% confidence limit [CL], 1.42-4.55) and remission (OR = 3.04; 95% CL, 1.57-5.87) were more likely with naltrexone-bupropion versus placebo. Greater baseline-to-week 4 reduction in PHQ-9 was associated with a higher likelihood of methamphetamine treatment response (OR = 3.74, 95% CL, 1.28-10.93) and explained 24.8% (95% CI, 6.7%-60.3%) of the effect of naltrexone-bupropion on methamphetamine treatment response. Use of naltrexone bupropion was associated with early reduction in depressive symptom severity compared to a placebo, which was associated with a higher likelihood of reduction in subsequent methamphetamine use. ClinicalTrials.gov identifier: NCT03078075.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 Trial
- Date Crossref
- 30/07/2025
- Éditeur
- Physicians Postgraduate Press, Inc
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Southwestern Medical Center pays non établi dans la noticeÉtablissement de santé
-
The University of Texas Southwestern Medical Center pays non établi dans la noticeÉtablissement de santé
-
National Institutes of Health pays non établi dans la noticeOrganisme public
-
National Institute on Drug Abuse pays non établi dans la noticeStructure de recherche
-
University of California Department of Psychiatry and Biobehavioral Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Neurobehavioral Systems pays non établi dans la noticeInstitution
-
Columbia University Irving Medical Center Department of Psychiatry pays non établi dans la noticeÉtablissement de santé
-
The University of Texas Health Science Center Department of Psychiatry and Behavioral Sciences pays non établi dans la noticeUniversité ou école supérieure
-
San Francisco Department of Public Health pays non établi dans la noticeÉtablissement de santé
-
University of San Francisco pays non établi dans la noticeUniversité ou école supérieure
-
Hennepin Healthcare Research Institute pays non établi dans la noticeStructure de recherche
-
Center for Depression Research and Clinical Care MD pays non établi dans la noticeÉtablissement de santé
Southwestern Medical Center, The University of Texas Southwestern Medical Center et National Institutes of Health, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.